RhoG, a member of the Rho family of GTPases, has been implicated as a regulator of the actin cytoskeleton. In this study, we show a novel function for the small GTPase RhoG on the regulation of the interferon-c promoter and nuclear factor of activated T cells (NFAT) gene transcription in lymphocytes. Optimal function of RhoG for the expression of these genes requires a calcium signal, normally provided by the antigen receptor. In addition, RhoG potentiation of NFAT requires the indirect activity of Rac and Cdc42; however, pathways distinct from those activated by Rac and Cdc42 mediate RhoG activation of NFAT-dependent transcription. Using effector domain mutants of RhoG we found that its ability to potentiate NFAT-dependent transcription correlates with its capacity to increase actin polymerization, supporting the suggestion that NFAT-dependent transcription is an actin-dependent process. RhoG also promotes T-cell spreading on fibronectin, a property that is independent of its ability to enhance NFAT-dependent transcription. Hence, these results implicate RhoG in leukocyte trafficking and the control of gene expression induced in response to antigen encounter.
Introduction
Signalling events initiated by the antigen receptor on lymphocytes mediate B-and T-lymphocyte development and control the proliferation and differentiation of mature lymphocytes in the peripheral lymphoid organs. Antigen receptors trigger multiple pathways, which result in changes in protein and lipid phosphorylation, activation of guanine nucleotide exchange factors, rearrangement of the actin cytoskeleton and release of intracellular calcium. Vav proteins are rapidly phosphorylated and activated upon antigen receptor engagement and provide a link from the antigen receptor to the activation of Rho GTPases (Bustelo, 2000) .
The Rho family of monomeric GTPases consists of about 20 GTP binding proteins. The best characterized of these -RhoA, Rac-1, Rac-2 and Cdc42 -have all been shown to function in lymphocyte signal transduction. Cdc42 has been implicated in polarization of the lymphocyte actin and microtubule cytoskeleton (Stowers et al., 1995) as well as NFAT-dependent transcription (Holsinger et al., 1998; Yablonski et al., 1998) . Transgenic mice that overexpress constitutively active Cdc42 under the control of T-cell-specific regulatory elements display enhanced apoptosis of immature and mature T cells (Na et al., 1999) . In lymphocytes, Rac-1 has been implicated in the regulation of the actin cytoskeleton (Arrieumerlou et al., 2000) , JNK activation (Hashimoto et al., 1998; Jacinto et al., 1998) , NFATdependent transcription (Genot et al., 1996; Holsinger et al., 1998) and cytoxicity (Billadeau et al., 1998) . Recent studies with transgenic mice expressing active Rac-1 in the T-cell lineage indicate that Rac-1 participates in the transition of early thymocytes through a developmental checkpoint that is dependent upon pre-TCR signal transduction. Furthermore, it was shown that active Rac-1 could restore the ability of Vav-1-deficient thymocytes to pass through this checkpoint, suggesting Rac-1 may be downstream of Vav-1 in early thymocytes (Gomez et al., 2000) . Moreover, Rac-1 modulates TCR signals to switch thymocytes from positive selection to negative selection, which implicates this molecule as a regulator of central tolerance . Overexpression of active Rac-2 in the T-cell lineage of transgenic mice has been reported to lead to thymic atrophy and a decrease in the number of mature thymocytes (Lores et al., 1997) . By contrast, T lymphocytes deficient in Rac-2 are impaired in their ability to polarize their cytokine transcription profile toward the Th1 lineage (Li et al., 2000) . Several lines of evidence suggest that Rac-2 regulates B-cell function. Rac-2-deficient mice display reduction in peritoneal B1a cells and marginal zone B cells. In addition, Ca 2+ flux in response to BCR and CD19 co-ligation is reduced (Croker et al., 2002) .
The role of Rho proteins in lymphocyte signalling and development has been investigated using the Clostridium botulinum C3 toxin that ADP-ribosylates and inactivates the GTPasa. C3 toxin inhibits cell-mediated cytotoxicity (Lang et al., 1992) ; C3 also inhibits the TCR-induced sustained increase in intracellular Ca 2+ and IL2 gene expression (Angkachatchai and Finkel, 1999) . The uses of transgenic mice that express C3 in the developing thymus indicate that Rho proteins control multiple checkpoints during the differentiation of T cells in the thymus Henning et al., 1997) . Inhibition of RhoA leads to apoptosis of early thymocytes that appear to be p53 dependent (Costello et al., 2000) . Furthermore, the proliferative expansion and decreased expression of CD2, which is a hallmark of differentiation of early thymocytes, as a consequence of pre-TCR signalling, are both dependent upon RhoA function (Henning and Cantrell, 1998) . However, transgenic mice expressing constitutively active RhoA showed that this protein is not sufficient to induce preT-cell differentiation in the absence of normal pre-TCR function. In contrast, thymocytes expressing RhoAV14 were hyper-responsive in terms of TCR abinduced proliferation and also showed augmented positive selection when expressing defined TCR complexes, implying RhoA as a positive regulator (Corre et al., 2001) .
The Rho family member RhoG was identified as a serum inducible gene in fibroblasts and is most similar in structure to the Cdc42 and Rac proteins (Vincent et al., 1992) . Functional studies indicate that a mutant active form of RhoG (RhoGV12), which results from the substitution of the glycine residue at position 12 to valine, cooperates with Ras and Rac to mediate cellular transformation (Roux et al., 1997) . GTP-RhoG can activate the stress kinase (JNK) but not the ERK pathway in fibroblasts (Roux et al., 1997) . Constitutively active RhoG induces morphological and cytoskeletal changes in fibroblastoid cells similar to those induced by the combination of active Rac and Cdc42, a property that is blocked by dominant negative versions of Rac and Cdc42 (Gauthier-Rouvire et al., 1998) . These studies have led to suggestions that in certain cell types RhoG may function upstream of both Rac and Cdc42. Interestingly, it has been suggested that RhoG may be distinct from Rac and Cdc42 in terms of effector binding partners, since it does not interact with CRIB domains (Gauthier-Rouvire et al., 1998) . Recent work has suggested that the Vav proteins can act as exchange factors for RhoG (Schuebel et al., 1998; Movilla and Bustelo, 1999) . Given the essential role of Vav proteins in lymphocyte development and function, we performed experiments to test for a role of RhoG in lymphocyte signalling. First, we demonstrate that RhoG regulates gene transcription in both B and T cells. Moreover, we show that neither Rac-1 nor Cdc42 lies downstream of RhoG in this signalling cascade. Second, using effector domain mutants of RhoG we show that the ability of RhoG to potentiate NFAT-dependent transcription cannot be dissociated from its ability to promote actin polymerization, supporting the suggestion that NFAT-dependent transcription is an actindependent process. Finally, RhoG also promotes cytoskeletal reorganization in T cells in response to fibronectin binding. These results implicate RhoG in leukocyte trafficking and the control of gene expression.
Results

RhoG potentiates gene transcription in lymphocytes
RhoG is expressed at high levels in both B and T lymphocytes (data not shown). To examine the biological function of RhoG in T lymphocytes, we expressed a myc tag version of RhoG in Jurkat T cells together with a luciferase reporter gene under the control of the nuclear factor of activated T cells (NFAT) regulatory sequences derived from the IL-2 promoter (IL-2/NFAT-Luc). Overexpression of RhoG induced a modest increase in NFAT-dependent transcription in unstimulated cells, but led to a substantial increase in NFAT dependent transcription elicited as a consequence of antigen receptor crosslinking with antibodies to the TCR/CD3 complex ( Figure 1a ). The ability of RhoG to potentiate NFAT-dependent transcription was not restricted to T cells, as Bal17 B cells cotransfected with IL-2/NFAT-Luc and RhoG also demonstrated a potentiation of NFAT-dependent transcription in a dose-dependent manner following BCR crosslinking (Figure 1b) . To further evaluate the requirement for RhoG in TCR-induced NFATdependent transcription, the endogenous RhoG protein was inhibited and IL-2/NFAT-Luc activity measured in Jurkat cells stimulated through their antigen receptor. We first used RhoGN17, a mutation that acts as a dominant negative version of the protein for others GTPases such as Rac-1 or Cdc42. As shown in Figure 1c , RhoGN17 does not affect anti-CD3-induced NFAT activation. The most likely explanation is that RhoGN17 has no inhibitory effect in this system, as previously reported using fibroblastic cells (Blangy et al., 2000) . A similar situation was described for Rap1A, whose predicted dominant negative version (S17N) has no inhibitory effect on some systems (Kitayama et al., 1990; Maly et al., 1994; Gabig et al., 1995; vandenBerghe et al., 1997) . Inhibition of RhoG was achieved expressing a 275-aa C-terminal fragment of RhoGIP22, a protein that has previously been reported to selectively block RhoG downstream signalling (Blangy et al., 2000) . The specific inhibitory effect of the RhoGIP122 fragment on T cells was tested in two different ways. First, increasing amounts of the RhoGIP122 fragment blocked NFAT-dependent transcription enhanced by constitutively active RhoG in combination with ionomycin (see below and Figure 1d) . Secondly, the inhibitory fragment of RhoGIP122 reduced antigen receptor potentiation of NFAT-dependent transcription, and the extent of this inhibition was proportional to the amount of plasmid transfected (Figure 1e ). Taken together, these results implicate RhoG as an intermediate between lymphocyte antigen receptors and nuclear transcription.
NFAT-dependent transcription requires the integration of separate signalling pathways, in particular, a PKC signal and a calcium signal, neither of which by itself is sufficient to activate transcription optimally. Whereas PKC is a positive regulator of the activating protein-1 (AP-1) family of transcription factors, the calcium signal acts on calcineurin promoting the translocation of NFAT transcription factors to the nucleus. These pathways can be mimicked by phorbol ester and calcium ionophore respectively (Crabtree, 1989) . To establish whether RhoG was preferentially activating on one or both pathways, we transfected T cells with wild-type RhoG and stimulated with either PMA or ionomycin. The increase in NFAT-dependent transcription promoted by RhoG could be further augmented by the addition of ionomycin (Figure 2a ), while addition of PMA did not lead to further increases in transcription (data not shown). Constitutively active RhoG further augmented NFAT-dependent transcription (Figure 2a ). In agreement with these results, RhoGV12 was able to potentiate an AP-1 luciferase reporter, suggesting that the role of RhoG in NFAT induction could be due to its ability to stimulate AP-1 activity (Figure 2b ).
In addition to the regulation of the IL-2 gene, the NFAT/AP-1 complex promotes the expression of various cytokines, among them interferon g (IFN-g). To examine further the role of RhoG in gene transcription, we assayed its ability to promote IFN-g transcription by cotransfecting RhoGV12 with a reporter construct containing the luciferase gene driven by the IFN-g promoter. The constitutively active form of RhoG showed a stimulatory effect on the IFN-g reporter, which was further increased by the addition of ionomycin ( Figure 2c ). We conclude that RhoG regulates cytokine gene transcription in B and T lymphocytes at least in part by modulating AP-1 function.
RhoG potentiation of NFAT requires the function of Rac-1 and Cdc42
The mechanisms by which RhoG regulates gene transcription are not known. However, RhoG-mediated cytoskeletal reorganization in fibroblasts and neuronal cells has been shown to require the function of Rac and Cdc42 (Gauthier-Rouvire et al., 1998) . To establish the requirement for Rac and Cdc42 in the enhancement of NFAT-dependent transcription by RhoG, we coexpressed Rac-1N17 and Cdc42N17 together with RhoGV12 in Jurkat cells. Rac-1N17 completely abolished the effect of RhoGV12 on NFAT-dependent transcription while Cdc42N17 partially inhibited the RhoGV12 effect ( Figure 3a) . These results suggested that either RhoG can activate Rac and Cdc42 in a GTPase cascade or that Rac and Cdc42 are required in parallel pathways that are necessary for NFAT-dependent transcription. To determine whether RhoG can activate Rac and Cdc42 in T cells, we transfected plasmids encoding myc-tagged versions of wild-type Rac-1 or Cdc42 together with RhoGV12. We then used affinity purification with the CRIB domain of PAK to determine the amount of each GTPase in the GTP-bound form (Manser et al., 1998; Benard et al., 1999) . In these assays, cotransfection of Oncovav-1, which possesses constitutively active GEF activity, served as a positive control and led to a clear activation of both Rac-1 and Cdc42 (Figure 3b and c). By contrast, RhoGV12 failed to give rise to an increase in GTP-bound Rac-1 or Cdc42 (Figures 3b and c) . Our results suggest that, in T lymphocytes, RhoG does not activate Rac-1 or Cdc42, but that these GTPases perform roles in additional signalling pathways that are necessary for NFATdependent transcription.
RhoG is activated downstream of Vav-1
To develop an assay to detect active RhoG, we took advantage of the fact that the 275 aa C-terminal fragment of RhoGIP122 selectively interacts with the GTP bound form of RhoG (Blangy et al., 2000) . As an initial test, a fusion protein of RhoGIP122 with glutathione S-transferase (GST-RhoGIP122) was coupled to glutathione beads and incubated with lysates of Jurkat cells expressing myc-tagged versions of wtRhoG and RhoGV12. The beads were rinsed and the retained proteins analysed by Western blot using anti-myc mAb. As expected, GSTRhoGIP122 retained recombinant RhoGV12 but no In each section, the bottom panels show the relative expression of the transfected proteins in a representative experiment as determined by blotting whole-cell lysates with anti-myc using 9E10
RhoG modulates NFAT activation in lymphocytes E Vigorito et al detectable wtRhoG was observed (Figure 4a ). In addition, the interaction is specific for RhoGIP122 as virtually no RhoGV12 was detected using GST alone. Furthermore, RhoGIP122 specifically interacts with GTP-RhoG but not GTP-Rac-1 or GTP-Cdc42 (Figure 4b ). To assay whether RhoG was activated downstream of Vav-1, Jurkat cells were cotransfected with wtRhoG and Oncovav-1. Subsequently, GTP-RhoG was recovered from lysates using Rho-GIP122. Active RhoG was clearly detected in cells expressing Oncovav-1 (Figure 4c ). The reduced levels of GTP-RhoG detected in the oncoVav-1-transfected cells compared with GTP-Rac1 or GTP-Cdc42 under similar conditions could reflect that PAK is more efficient than RhoGIP122 (i.e. difference in affinities) for precipitating the activated form of the GTPases. Another explanation could be that Oncovav1 is a more efficient activator of Rac1/Cdc42 than RhoG. RhoG modulates NFAT activation in lymphocytes E Vigorito et al
RhoG effector domain mutants that activate transcription interact with RhoGIP122 and also promote actin polymerization
The switch I region of GTPases has been identified as a critical domain required for their interaction with a number of effector molecules (Bishop and Hall, 2000) . Mutations of these residues provide a useful tool to delineate signalling pathways involved in different cellular functions. Based on this rationale, we prepared a panel of myc-tagged constitutively active RhoG mutants, according to previous mutants described for Rac-1 and Cdc42 (Lamarche et al., 1996; Westwick et al., 1997; Tapon et al., 1998) , and tested their ability to promote NFAT-dependent transcription or to induce the formation of F-actin. Mutation of residues Y32, T35 and F37 abolished the ability of RhoGV12 to potentiate NFAT-dependent transcription, an effect that could not be attributed to the low-level expression of the mutant proteins; however, mutation of residues D38 and Y40 had no effect on transcription (Figure 5a ). Subsequently, we examined the ability of these mutants to bind RhoGIP122. To this end, lysates from Jurkat cells expressing myc-tagged RhoGV12 or effector domain mutant proteins of RhoGV12 were incubated with a GST-RhoGIP122 fusion protein coupled to glutathione beads and interacting proteins were detected by Western blot. Mutation of residues Y32, T35 and F37 highly reduced the ability of RhoGV12 to interact with RhoGIP122, whereas mutation of residues D38 and Y40 had no effect on this interaction (Figure 5b ). We next tested the effect of the RhoGV12 effector domain mutants on actin polymerization. Mutation of residues Y32, T35 and F37 abolished the ability of RhoGV12 to induce the formation of actin filaments as assessed by intracellular staining with phalloidin ( Figure 5c ). Indeed, the T35 and F37 mutations led to significant inhibition of basal actin polymerization. By contrast, the D38 and Y40 mutants retained their ability to induce F-actin formation (Figure 5c ). Thus, we find a correlation between the ability of these mutants to induce actin polymerization and promote NFATdependent transcription. In addition, cytochalasin D -an inhibitor of actin polymerization -inhibited NFAT activation induced by RhoGV12 (Figure 5d ).
RhoG effector domain mutants and cell morphology on fibronectin
Leukocytes bind to extracellular matrix components and undergo morphological changes that precede their migration into sites of injury and inflammation. These changes are essential for the initiation of the immune response. The spreading of Jurkat cells on fibronectin-coated surfaces (Faull et al., 1994) serves as RhoG modulates NFAT activation in lymphocytes E Vigorito et al a model for studying these early changes in leukocyte morphology and has previously been shown to be promoted by Rac-1V12 (D'Souza-Schorey et al., 1998).
To examine the effect of RhoG in T-lymphocyte morphology, we seeded Jurkat cells that had been transfected with RhoGV12 onto fibronectin-coated coverslips. RhoGV12 induced long multiple protrusions (Figure 6a , panels g and h), a distinct phenotype from that induced by Rac-1 (c, d) or Cdc42 (e, f) (D'SouzaSchorey et al., 1998). Thus, like Rac-1V12, RhoGV12 can regulate the interaction of cells with fibronectin on T lymphocytes. We then analysed the morphology of RhoGV12 effector domain mutants on fibronectin and quantified their effect by determining the proportion of transfected cells that showed a RhoG-like morphology (Figure 6a,b) . The Y32 and Y40 mutants retained similar morphology to the RhoGV12 mutant; however, mutation of residues T35 and D38 resulted in round cells (Figure 6a) RhoG modulates NFAT activation in lymphocytes E Vigorito et al driven by the antigen receptors, as our assay was not sensitive enough to detect GTP-RhoG in cells activated by antigen receptor cross-linking overexpressing wtRhoG. These results prompted us to examine the mechanism by which RhoG regulates NFAT-dependent transcription. Expression of constitutively activated RhoG induced a response in T cells that can synergize with a calcium signal for NFAT induction. This observation, together with the ability of RhoG to induce AP-1-dependent gene transcription in other cell types, suggests that RhoG potentiates NFAT/AP-1-mediated gene transcription by controlling intracellular signalling cascades that regulate AP-1 activation. Previous studies have identified a similar mechanism in the control of NFAT/AP-1 activity by other GTPases such us Rac-1 and Cdc42, thereby raising the possibility that these proteins act in a common signalling pathway to regulate AP-1 activity.
Our data suggest that the ability of RhoG to potentiate NFAT-dependent transcription requires the function of Rac-1 and ionomycin since coexpression of Rac-1N17 abrogated NFAT activation (Figure 3a) . Surprisingly, Cdc42N17 could only partially block NFAT gene transcription mediated by RhoGV12 and ionomycin. The results presented here contrast with previous observations in neuronal cells and fibroblasts in which RhoG-induced cytoskeletal reorganization requires the activity of both Rac-1 and Cdc42 (Gauthier-Rouvire et al., 1998; Katoh et al., 2000) . In addition, a previous study has indicated that RhoG regulates the activation of both Rac-1 and Cdc42 (Katoh et al., 2000) . However, as shown in Figure 3b and c, RhoG does not lie directly upstream of either Rac-1 or Cdc42 in lymphocytes since expression of V12RhoGUI2 did not result in an increase in the GTPbound form of either GTPases. This discrepancy may reflect differences in signal transduction mechanisms that have evolved in different cell lineages. Hence, we favour the suggestion that in T cells, Rac-1 and Cdc42 regulate pathways distinct from RhoG that are required for NFAT-dependent transcription, as it has been shown that Rac and Cdc42 are activated downstream of the antigen receptors (Kuhne et al., 2000; Krawczyk et al., 2000; Reynolds et al., 2002) . The identification of RhoG modulates NFAT activation in lymphocytes E Vigorito et al an essential role for PAK in the activation of NFAT (Wardenburg et al., 1998; Yablonski et al., 1998) adds weight to our suggestion because PAK is regulated by both Rac and Cdc42 but not by RhoG (GauthierRouvire et al., 1998) . Despite the structural similarity of RhoG to Rac and Cdc42, no common effectors have been identified so far. One candidate effector for RhoG is RhoGIP122, which has been reported to interact specifically with GTPRhoG by the yeast two-hybrid system. In this regard, we provide three lines of evidence to support this notion. First, RhoGIP122 interacts with RhoGV12 but not with wtRhoG expressed in Jurkat cells. Second, the effectorloop mutants RhoGV12K32, RhoGV12A35 and RhoG-V12A37 abolished the interaction between RhoG and RhoGIP122. Finally, the inability of RhoG to interact with RhoGIP122 correlates with its inability to promote NFAT-dependent transcription and to induce actin polymerization. The fact that we could not dissociate NFAT activation from actin polymerization, in addition to the blocking effect of cytochalasin D on NFATinduced activation by RhoGV12, raises the possibility that RhoG regulates gene transcription by its effects on cytoskeletal reorganization. This idea is supported by the observation that disruption of filamentous actin by cytochalasin D prevents NFAT activation (Holsinger et al., 1998) . In addition, the correlation observed between NFAT activation, RhoGIP122 binding and RhoG modulates NFAT activation in lymphocytes E Vigorito et al actin polymerization activity prompted us to speculate that RhoGIP122 may be a mediator in these cellular processes. However, the biological significance of this interaction remains unclear. Little is known about RhoGIP122. RhoGIP122 was originally cloned from a yeast two-hybrid screen of a Jurkat cDNA library (Vignal et al., 2001) . It is expressed in lymphoid organs such as spleen, bone marrow, lymph nodes as well as in several B cell lines (data not shown). The deduced amino-acid sequence displayed significant homology with sarcolemmal-associated protein 3 (SLAP3), a protein expressed in cardiac cells (Wielowieyski et al., 2000) . Although the physiological role of SLAPs or SLAP-related proteins is not known, these proteins can be found at the plasma membrane as well as on intracellular membranes, suggesting a role in vesicle trafficking (Wielowieyski et al., 2000) . Further insights into RhoGIP122 function may provide a better understanding of the mechanism by which the RhoGRhoGIP122 axis can regulate actin reorganization and gene transcription.
The potential for RhoG to function through multiple effectors has also been established in this study. On the one hand, we identified effector mutants that failed to promote actin polymerization or NFAT-dependent transcription but retained the ability to promote morphological changes on fibronectin. On the other hand, we also describe an effector mutant that has lost the ability to induce morphological changes on fibronectin but is still able to promote actin polymerization and NFAT-dependent transcription. The dissociation of the pathways activated by RhoG that give rise to actin polymerization from the ones that drive morphogenic activity implies a complex role for RhoG in the regulation of cytoskeleton. In fact, it has been described that RhoG morphogenic activity in fibroblasts requires the microtubule network, with kinectin being an important mediator connecting RhoG with the microtubule filaments (Vignal et al., 2001) . In this regard, RhoG is distinct from Rac-1 and Cdc42. The morphological changes induced by RhoG in T cells on fibronectin were characterized by the extension of long projections from the cytoplasmic membrane, which were different from those induced by Rac-1 or Cdc42. Whether or not kinectin regulates RhoG-mediated cell spreading in lymphocytes remains to be determined.
In conclusion, RhoG regulates multiple functions in lymphocytes. First, RhoG regulates gene expression, as revealed by its effects on IFN-g transcription in T cells and NFAT-dependent transcription in response to antigen stimulation in both B and T cells. Second, mutational analysis has revealed that the ability of RhoG to regulate NFAT-mediated gene transcription correlates with its ability to promote F-actin formation. Lastly, RhoG acts as a morphogen in Jurkat cells plated onto fibronectin, utilizing signalling pathways other than those responsible for NFAT activity or actin regulation. Identification and characterization of RhoG effectors should provide new insights into the molecular mechanisms that integrate leukocyte migration with gene expression.
Materials and Methods
Plasmids
The luciferase reporter constructs used in this paper were as follows: p(NFAT) 3 IL2-Luc (from D Williams), which contains three copies of the distal IL-2 promoter NFAT site upstream of the À80 to +35 region of the IL-2 promoter, inserted into pGL2-Basic (Promega). The AP-1 luciferase reporter construct was p(AP-1) 3 -Luc, from S Cook, which contains three copies of the AP-1 sequence, and the luciferase reporter construct containing the distal region of the IFNg promoter has been previously described (Rincon et al., 1998) . WtRhoG was subcloned in the expression plasmid pEF-BOS, which was provided by Amnon Altman. RhoGV12 mutation was generated by site-directed mutagenesis using wtRhoG in pEF-BOS as a template by Stratagene Quickchange kit following the manufacturer's instructions. The RhogN17 construct used is a pCDNA3 version. Wild-type RhoG was subcloned from cDNA obtained by reverse transcription of NK cell total RNA. The N17 mutant was generated using the Stratagene site-directed mutagenesis kit and the following overlapping oligonucleotides (+) strand 5 0 -GATGGGGCTGTGGGCAAGaacTGCCT-GCTCATCTGCTAC-3 and (À) strand 5 0 -GTAGCAGATGAGCAGGCAgttCTTGCCCACAGCCCCATC-3 0 . The lowercase letters represent the T17N mutation. The clones obtained by mutagenesis were fully sequenced. Expression plasmids for Rac-1V12 and Cdc42V12 were from D Cantrell, wtRac-1, Rac-1N17, wtCdc42 and Cdc42N17 were a gift of A Hall, and GST-PAK was from Ed Manser. Myc-Onco-Vav-1 has previously been described (Schuebel et al., 1996) . The RhoG binding site (RBS) of RhoGIP122 was amplified by PCR and subcloned into pGEX-3X (Pharmacia) using BamH1 and EcoRI restriction sites introduced by the PCR primers for preparing a GST-RhoGIP122 fusion protein. The GFP expressing plasmid pCMV-EGFP-NLS was a gift from E Joly. All constructs and derivatives were sequenced to verify its structure.
Cell culture, transfections and luciferase reporter assays
Jurkat and Bal-17 cells were grown in 5% heatinactivated FCS RPMI supplemented with 2 mm lglutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Jurkat cells (1 Â 10 7 ) were transfected with 10 mg of a mammalian expression vector encoding SV40 large T antigen and 10 mg of a reporter construct plus the indicated amount of co-transfected plasmid or empty expression vector at 250 mV and 960 mF using a Bio-Rad gene pulser. Samples of 2 Â 10 5 cells were incubated for 18 h post-transfection and then stimulated with medium alone or 2 mg/ml OKT3 (monoclonal anti-human CD3) for 6 h. Alternatively, cells were pretreated with 10 mm cytochalasin D (Sigma) for 30 min followed by treatment with 10 mm ionomycin (Sigma) for 6 h as indicated in the figure legends. Subsequently, cells were harvested, lysed in 100 ml of cell culture lysis reagent (Promega), and luciferase activity was measured using a Top Count NXT Luminescence Counter (Packard) according to the manufacturer's instructions. Bal-17 murine B lymphoma cells (2 Â 10 7 per transfection), growing in log phase, were electroporated with 10 mg of reporter construct plus the indicated amount of cotransfected plasmid or empty expression vector at 300 mV and 960 mF using a Bio-Rad gene pulser. After transfection, cells were stimulated with 2 mg/ml b7.6 (monoclonal anti-mouse IgM) for 18 h. Subsequently, luciferase activity was measured as described for Jurkat cells. Lysates were corrected for protein levels using Bio-Rad's DC protein assay. In all luciferase assays, empty expression vector DNA was used to equalize the amount of input DNA so that the amounts of EF-1a (elongation factor-1a) promoter and other regulatory elements were kept constant.
Actin polymerization assay
Actin polymerization quantification was carried out as described previously (Villalba et al., 2000) with some modifications. Briefly, T-Ag Jurkat cells were transfected with the indicated plasmids plus 5 mg pCMV-EGFP-NLS and cultured for 18 h. Subsequently, 1 Â 10 6 cells were fixed with one volume of 3.7% paraformaldehyde /PBS for 15 min at room temperature, followed by blocking with PBS/1%BSA/0.1%NaN 3 for 15 min at room temperature. Cells were permeabilized in PBS/ 1%BSA/0.1%NaN 3 /0.05%saponin for 30 min at 41C, and resuspended in the same solution plus 300 ng/ml TRITC-conjugated phalloidin (Sigma) for an additional 30 min at 41C in the dark. After washing the samples 3 times in cold PBS/1%BSA/0.1%NaN 3 , GFP-gated cells were analysed by flow cytometry using Cellquest software (Becton-Dickinson) by a FACSCalibur (BectonDickinson).
Immunofluorescence microscopy
Jurkat cells were transfected with the indicated plasmids and seeded onto fibronectin-coated coverslips for 16 h. Alternatively, cells were preincubated 30 min with 10 mm cytochalasin D before being added to the fibronectincoated cover slips. Subsequently, cells were rinsed, the adherent cells were fixed, permeabilized and labelled with anti-myc (9E10) and secondary antibodies. Actin filaments were visualized by staining with TRITCphalloidin. Coverslips were mounted and a SPOT digital camera (Diagnostic Inst.) using SPOT advanced software (Diagnostic Inst.) connected to an Axioplan 2 (Zeiss) microscope recorded images of the cells.
GST-PAK and GST-RhoGIP122 pull-down assays GTP-Rac-1 and GTP-Cdc42 were measured according to the modified method of Benard (Benard et al., 1999) . Briefly, 16 h after transfection cells lysed in 1 ml of lysis buffer (50 mm Tris-HCl pH 7.4, 150 mm NaCl, 10 mm MgCl 2 , 1% Nonidet P-40, 1 mm dithiothrietol and protease inhibitors). Cell lysates were centrifuged for 2 min at 14 000 g and 50 ml of the supernatants were used for checking protein expression. The remaining lysates were incubated with 20 mg of GST-PAK coupled to glutathione-sepharose beads for 20 min at 41C. After washing the beads 3 times with wash buffer (50 mm TrisHCl pH 7.4, 500 mm NaCl, 10 mm MgCl 2 , 0.1% Nonidet P-40, 1 mm dithiothrietol and protease inhibitors), the bound proteins were eluted in Laemmli sample buffer, separated in 12% SDS-PAGE and blotted with anti-myc 9E10 monoclonal antibody. For detecting GTP-RhoG transfected cells were lysed in 1 ml of lysis buffer (50 mm Tris-HCl pH 7.4, 150 mm NaCl, 10 mm MgCl 2 , 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS, 1 mm dithiothrietol and protease inhibitors). Cell lysates were centrifuged for 2 min at 14 000 g and 50 ml of the supernatants were used for checking protein expression. The remaining lysates were incubated with 100 mg of GST-RhoGIP122 coupled to glutathionesepharose beads for 20 min at 41C. After washing the beads 3 times with wash buffer, the bound proteins were eluted in Laemmli sample buffer, separated in 12% SDS-PAGE and blotted with anti-myc 9E10.
